JP2006526025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006526025A5 JP2006526025A5 JP2006514998A JP2006514998A JP2006526025A5 JP 2006526025 A5 JP2006526025 A5 JP 2006526025A5 JP 2006514998 A JP2006514998 A JP 2006514998A JP 2006514998 A JP2006514998 A JP 2006514998A JP 2006526025 A5 JP2006526025 A5 JP 2006526025A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- infection
- och
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- 229940127557 pharmaceutical product Drugs 0.000 claims 13
- 241001465754 Metazoa Species 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 9
- 208000015181 infectious disease Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000025865 Ulcer Diseases 0.000 claims 6
- 206010023332 keratitis Diseases 0.000 claims 6
- 231100000397 ulcer Toxicity 0.000 claims 6
- 241000282412 Homo Species 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 201000011066 hemangioma Diseases 0.000 claims 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 2
- 208000009043 Chemical Burns Diseases 0.000 claims 2
- 208000002691 Choroiditis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010010996 Corneal degeneration Diseases 0.000 claims 2
- 206010011017 Corneal graft rejection Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000019878 Eales disease Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 241001653121 Glenoides Species 0.000 claims 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 206010051151 Hyperviscosity syndrome Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 201000004404 Neurofibroma Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 208000003971 Posterior uveitis Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010039705 Scleritis Diseases 0.000 claims 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010058990 Venous occlusion Diseases 0.000 claims 2
- 206010047663 Vitritis Diseases 0.000 claims 2
- 208000004064 acoustic neuroma Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000015322 bone marrow disease Diseases 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 208000013653 hyalitis Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 2
- 208000001491 myopia Diseases 0.000 claims 2
- 230000004379 myopia Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 208000006379 syphilis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 206010044325 trachoma Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010044583 Bartonella Infections Diseases 0.000 claims 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 206010019973 Herpes virus infection Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 206010037649 Pyogenic granuloma Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 206010064996 Ulcerative keratitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000000022 bacteriostatic agent Substances 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 206010004145 bartonellosis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 201000007717 corneal ulcer Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004177 elastic tissue Anatomy 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000011278 mitosis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002324 mouth wash Substances 0.000 claims 1
- 229940051866 mouthwash Drugs 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000006476 shipyard eye Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- -1 solutes Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000001364 upper extremity Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 C[C@](CC1)(C(CC2)C(CC3)C1c1c3cc(*)c(C#CC)c1)C2=O Chemical compound C[C@](CC1)(C(CC2)C(CC3)C1c1c3cc(*)c(C#CC)c1)C2=O 0.000 description 10
- PJTVFFZBOJIMCQ-ZXGDDTLZSA-N CCOc(cc(C1C(CC2)C(CCC3)[C@]3(C)CC1)c2c1)c1F Chemical compound CCOc(cc(C1C(CC2)C(CCC3)[C@]3(C)CC1)c2c1)c1F PJTVFFZBOJIMCQ-ZXGDDTLZSA-N 0.000 description 2
- WLQXUNJRKHLSPP-YWHZPUBESA-N CC(CC1)[C@@](C)(CC2)C1C(CCc1c3)C2c1cc(OC)c3F Chemical compound CC(CC1)[C@@](C)(CC2)C1C(CCc1c3)C2c1cc(OC)c3F WLQXUNJRKHLSPP-YWHZPUBESA-N 0.000 description 1
- YRNRHYOMFCWZSE-XXHOTSQFSA-N CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)/C3=C\C)c2c1)c1F Chemical compound CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)/C3=C\C)c2c1)c1F YRNRHYOMFCWZSE-XXHOTSQFSA-N 0.000 description 1
- NYKXFYHIFCXBLB-XXHOTSQFSA-N CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)/C3=C\C)c2c1)c1N Chemical compound CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)/C3=C\C)c2c1)c1N NYKXFYHIFCXBLB-XXHOTSQFSA-N 0.000 description 1
- FBVDZJTTXRGSKL-TZMLOSDDSA-N CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3=C)c2c1)c1N Chemical compound CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3=C)c2c1)c1N FBVDZJTTXRGSKL-TZMLOSDDSA-N 0.000 description 1
- ASCKFYQJTOLXOT-KBILMSAYSA-N CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3=O)c2c1)c1F Chemical compound CCOc(cc(C(CC1)C(CC2)C(CC3)[C@@]1(C)C3=O)c2c1)c1F ASCKFYQJTOLXOT-KBILMSAYSA-N 0.000 description 1
- CHRXOUVQBRGWDJ-SWVJVUJVSA-N CCOc(cc(C(CC1)C(CC2)C3[C@@]1(C)C(C)CC3)c2c1)c1F Chemical compound CCOc(cc(C(CC1)C(CC2)C3[C@@]1(C)C(C)CC3)c2c1)c1F CHRXOUVQBRGWDJ-SWVJVUJVSA-N 0.000 description 1
- DIFRSDYKUUDXAB-MGGPMZQCSA-N C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(C#CC)c4N)C2=O Chemical compound C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(C#CC)c4N)C2=O DIFRSDYKUUDXAB-MGGPMZQCSA-N 0.000 description 1
- QCVFFPDTXOXVPQ-DNAQETHLSA-N C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(OC)c4F)/C2=C\C Chemical compound C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(OC)c4F)/C2=C\C QCVFFPDTXOXVPQ-DNAQETHLSA-N 0.000 description 1
- VSNOHUREIAESJB-DNAQETHLSA-N C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(OC)c4N)/C2=C\C Chemical compound C[C@](CC1)(C(CC2)C(CCc3c4)C1c3cc(OC)c4N)/C2=C\C VSNOHUREIAESJB-DNAQETHLSA-N 0.000 description 1
- VSNOHUREIAESJB-KWAPHZHFSA-N C[C@](CC1)(C(CC2)[C@@H](CCc3c4)C1c3cc(OC)c4N)/C2=C\C Chemical compound C[C@](CC1)(C(CC2)[C@@H](CCc3c4)C1c3cc(OC)c4N)/C2=C\C VSNOHUREIAESJB-KWAPHZHFSA-N 0.000 description 1
- ZGDJPKSRBXRBSD-CBTMWXCYSA-N C[C@](CCC1)(CC2)C1C(CCc1c3)C2c1cc(OC)c3C(N)=O Chemical compound C[C@](CCC1)(CC2)C1C(CCc1c3)C2c1cc(OC)c3C(N)=O ZGDJPKSRBXRBSD-CBTMWXCYSA-N 0.000 description 1
- IBNKEIBYMIJVET-RYCRIANLSA-N C[C@](CCC1)(CC2)C1C(CCc1c3)C2c1cc(OC)c3F Chemical compound C[C@](CCC1)(CC2)C1C(CCc1c3)C2c1cc(OC)c3F IBNKEIBYMIJVET-RYCRIANLSA-N 0.000 description 1
- DRIRHJCVGPUFJV-NODKNVJMSA-N C[C@]1(CCC(C2CCc3c4)c3cc(OC)c4F)C2=CCC1=C Chemical compound C[C@]1(CCC(C2CCc3c4)c3cc(OC)c4F)C2=CCC1=C DRIRHJCVGPUFJV-NODKNVJMSA-N 0.000 description 1
Claims (31)
- 前記化合物は、1日の単位量、1日の単位量未満の量、又はそれを適当に分割した任意の量で投与されることを特徴とする、請求項4に記載の医薬品
- 前記化合物は、およそ0.1〜およそ300mg/kg/日の量で投与される、請求項4又は5に記載の医薬品。
- 前記化合物は、およそ0.5〜およそ50mg/kg/日の量で投与される、請求項4から6のいずれか一項に記載の医薬品。
- 前記化合物は、およそ1〜およそ10mg/kg/日の量で投与される、請求項4から7のいずれか一項に記載の医薬品。
- 前記化合物は、経口、非経口、経皮、局所、静脈内、皮下、筋内、皮内、点眼、硬膜外、気管内、舌下、口腔、直腸、膣内、経鼻または吸入投与されることを特徴とする、請求項4から8のいずれか一項に記載の医薬品。
- 前記化合物は、酸化防止剤、緩衝剤、静菌薬、液体キャリア、溶質、懸濁剤、増粘剤、着香料、ゼラチン、グリセリン、結合剤、潤滑剤、不活性希釈剤、防腐剤、界面活性剤、分散剤、生分解性ポリマー又はそれらの任意の組合せから選択される添加剤を含む組成物として投与される、請求項4から9のいずれか一項に記載の医薬品。
- 前記化合物は、錠剤、カプセル、トローチ剤、カシェ剤、溶液、懸濁液、エマルジョン、粉末、エーロゾル、坐剤、スプレー、芳香錠、軟膏、クリーム、ペースト、発泡体、ジェル、タンポン、ペッサリー、顆粒、ボーラス、うがい薬または経皮パッチの形態で投与される、請求項4から10のいずれか一項に記載の医薬品。
- 前記血管新生は、糖尿病性網膜症、未熟児網膜症、角膜移植片拒絶、血管新生緑内障、水晶体後線維増殖症、流行性角結膜炎、ビタミンA欠乏症、コンタクトレンズの過剰装着、アトピー性角膜炎、上輪部角膜炎、翼状片乾性角膜炎、シェーグレン症候群、酒さ性挫瘡、フリクテン症、梅毒、ミコバクテリア感染、脂質変性、化学的熱傷、細菌性潰瘍、真菌性潰瘍、単純ヘルペス感染、帯状ヘルペス感染、原生動物感染、カポジ肉腫、モーレン潰瘍、テリエン周辺角膜変性、辺縁潰瘍性角膜炎、外傷、関節炎、慢性関節リウマチ、多発性動脈炎、全身性狼瘡、ヴェーゲナー肉芽腫症、強膜炎、スティーヴンズ−ジョンソン疾患、放射状角膜切開、黄斑変性、鎌状赤血球貧血、サルコイド、弾性線維性仮性黄色腫、パジェット病、静脈閉塞症、動脈閉塞症、頸動脈閉塞性疾患、慢性ブドウ膜炎、慢性硝子体炎、ライム病、イールズ病、ベーチェット病、近視、視窩、シュタルガルト病、扁平部炎、慢性網膜剥離、過粘稠度症候群、トキソプラズマ症、レーザー照射後の合併症、線維性血管組織または線維組織の異常増殖、血管腫、オースラー−ウェーバー−ランデュ病、固形腫瘍、血液性の腫瘍、後天性免疫不全症候群、眼の血管新生疾患、加齢性黄斑変性、変形性関節症、慢性炎症により引き起こされる疾患、クローン病、潰瘍性大腸炎、横紋筋肉腫、網膜芽細胞腫、ユーイング肉腫、神経芽細胞腫、骨肉腫、白血病、乾癬、アテローム性動脈硬化症、類天疱瘡、網膜炎を引き起こす感染、脈絡膜炎を引き起こす感染、推定眼ヒストプラスマ症、ベスト病、増殖性硝子体網膜症、バルトネラ症、聴神経腫、神経線維腫、トラコーマ、又は化膿性肉芽腫に関連する、請求項4から11のいずれか一項に記載の医薬品。
- 前記眼の状態は、眼の新生血管疾患、糖尿病性網膜症、未熟児網膜症、黄斑変性、加齢性黄斑変性、角膜移植片拒絶、血管新生緑内障、水晶体後線維増殖症、コンタクトレンズの過剰装着、アトピー性角膜炎、上輪部角膜炎、翼状片乾性角膜炎、近視、慢性網膜剥離、視窩、テリエン周辺角膜変性、過粘稠度症候群、慢性ブドウ膜炎、慢性硝子体炎、推定眼ヒストプラスマ症、網膜炎、脈絡膜炎、増殖性硝子体網膜症、強膜炎、イールズ病、ベスト病、トラコーマ、扁平部炎、慢性炎症に起因するもの、レーザー照射後の合併症、又は放射状角膜切開である、請求項13に記載の医薬品。
- 前記炎症性または免疫性疾患は、慢性関節リウマチ、変形性関節症、潰瘍性大腸炎、クローン病、モーレン潰瘍、関節炎、サルコイドーシス、炎症性腸疾患、免疫性腸疾患、全身性狼瘡、扁平部炎、ヴェーゲナー症候群、スティーヴンズ−ジョンソン疾患、ベーチェット病、類天疱瘡、ライム病、又は後天性免疫不全症候群である、請求項15に記載の医薬品。
- 前記感染症は、梅毒、細菌性感染、ミコバクテリア感染、細菌性潰瘍、真菌性潰瘍、単純ヘルペス感染、帯状ヘルペス感染、原生動物感染、バルトネラ感染、又はトキソプラスマ症である、請求項17に記載の医薬品。
- 前記癌性疾患は、横紋筋肉腫、網膜芽細胞腫、ユーイング肉腫、神経芽細胞腫、聴神経腫、骨肉腫、神経線維腫、血管腫、乳癌、前立腺癌、腎細胞癌、脳腫瘍、卵巣癌、結腸癌、肝臓癌、肺癌、膀胱癌、皮膚黒色腫、カポジ肉腫、又は白血病である、請求項19に記載の医薬品。
- 前記血液疾患または血管疾患は、静脈閉塞症、動脈閉塞症、頸動脈閉塞性疾患、多発性動脈炎、アテローム性動脈硬化症、オースラー−ウェーバー−ランデュ病、鎌状赤血球貧血、白血病、骨髄の急性腫瘍性疾患、骨髄の慢性腫瘍性疾患、血管腫、遺伝性出血性毛細管拡張症、骨髄の疾患、貧血、血液凝固障害、リンパ節の腫脹、肝臓の腫脹、又は脾臓の腫脹である、請求項21に記載の医薬品。
- 前記骨髄の急性または慢性腫瘍性疾患は、多発性骨髄腫である、請求項22に記載の医薬品。
- 前記骨髄の急性または慢性腫瘍性疾患は、骨髄異形成症候群である、請求項22に記載の医薬品。
- 前記皮膚状態は、異常な創傷治癒、酒さ性挫瘡、化学的熱傷に起因するもの、又は乾癬である、請求項25に記載の医薬品。
- 前記腫瘍は、血液性の腫瘍、癌性の血液性の腫瘍、固形腫瘍、良性腫瘍、又は癌性腫瘍である、請求項27に記載の医薬品。
- 薬学的キャリアまたは賦形剤、および下記の化学式
Z’は、>C−F、>C−NH2、>CCONH2、>C−NHCOH、>C−OSO2NH2または>C−CHCH2から選択され、
Z”は、>C(H2)、>C(H)−CH3、>C=CH2、>C=CHCH3または>C=Oから選択されるが、但し、Z’が>C−OSO2NH2であり、かつZ”が>C(H2)または>C=Oである場合、Raは、−OCH3でも−OCH2CH3でもなく、Z’が>C−NH 2 である場合、Z”は>C=Oではない
で表される化合物を含む薬学的組成物であって、該化合物の含有量は、ヒトまたは動物に対して、1日の単位量、1日の単位量未満の量、又はそれを適当に分割した量で投与した場合に有効な量であることを特徴とする、薬学的組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47428803P | 2003-05-28 | 2003-05-28 | |
PCT/US2004/016831 WO2005030120A2 (en) | 2003-05-28 | 2004-05-28 | Antiangiogenic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006526025A JP2006526025A (ja) | 2006-11-16 |
JP2006526025A5 true JP2006526025A5 (ja) | 2007-07-26 |
Family
ID=34392892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006514998A Withdrawn JP2006526025A (ja) | 2003-05-28 | 2004-05-28 | 抗血管新生剤 |
Country Status (6)
Country | Link |
---|---|
US (3) | US7371741B2 (ja) |
EP (1) | EP1633367A2 (ja) |
JP (1) | JP2006526025A (ja) |
AU (1) | AU2004275693A1 (ja) |
CA (1) | CA2527074A1 (ja) |
WO (1) | WO2005030120A2 (ja) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
US20040214807A1 (en) * | 1993-08-06 | 2004-10-28 | D'amato Robert J. | Estrogenic compounds as anti-mitotic agents |
US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US7135581B2 (en) * | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
US7371741B2 (en) * | 2003-05-28 | 2008-05-13 | Entremed, Inc. | Estradiol derivatives and pharmaceutical compositions using same |
EP1735293A2 (en) * | 2004-03-09 | 2006-12-27 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
US20070004689A1 (en) * | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
AU2005222934B2 (en) * | 2004-03-12 | 2010-06-17 | Entremed, Inc. | Antiangiogenic agents |
WO2006058298A2 (en) * | 2004-11-29 | 2006-06-01 | Entremed, Inc. | A method of administering anti-angiogenic agents and a method of treating disease using same |
US20060264413A1 (en) | 2005-04-18 | 2006-11-23 | Sri International | Method and composition for inhibiting cell proliferation and angiogenesis |
US10174070B2 (en) | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
US20080119447A1 (en) * | 2005-09-30 | 2008-05-22 | James Yarger | 6-alkoxyalkyl estradiol derivatives and methods of use |
US8168621B2 (en) | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
US20070185069A1 (en) * | 2005-11-14 | 2007-08-09 | Plum Stacy M | Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents |
AU2007227256B2 (en) * | 2006-03-20 | 2012-10-04 | Entremed, Inc. | Disease modifying anti-arthritic activity of 2-methoxyestradiol |
WO2008094665A1 (en) * | 2007-01-31 | 2008-08-07 | Entremed, Inc. | Method of treating amyloidosis mediated diseases |
EP2170402B1 (en) | 2007-06-26 | 2015-03-25 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
CZ2008275A3 (cs) * | 2008-05-05 | 2009-05-06 | Prírodovedecká Fakulta Uk | Ligandy estrogenových receptoru alfa a beta, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují |
US20110190323A1 (en) * | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
US20120190659A1 (en) * | 2009-04-22 | 2012-07-26 | Children's Medical Center Corporation | Angiogenesis inhibitors |
AU2011242988B2 (en) * | 2010-04-19 | 2013-02-07 | Sri International | Compositions and method for the treatment of multiple myeloma |
FR2975008B1 (fr) * | 2011-05-13 | 2014-03-07 | Inst Biophytis | Utilisation de composes et composition pour le traitement de la degenerescence maculaire liee a l'age (dmla) |
EA201891279A1 (ru) | 2013-12-24 | 2019-01-31 | Президент Энд Феллоус Оф Гарвард Колледж | Аналоги кортистатина, их синтез и применения |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
KR20210044589A (ko) * | 2019-10-15 | 2021-04-23 | 재단법인 한국파스퇴르연구소 | 2-메톡시에스트라디올 유도체 및 이들의 의약 용도 |
CN111041062B (zh) * | 2019-12-19 | 2021-11-16 | 山东赛托生物科技股份有限公司 | 一种甾体化合物的制备方法 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US596245A (en) * | 1897-12-28 | Hinge for ink-well caps | ||
US2584271A (en) | 1948-06-19 | 1952-02-05 | Searle & Co | Steroid derivatives and method for producing the same |
US3166577A (en) | 1956-05-29 | 1965-01-19 | Syntex Corp | 1, 2-dimethyl estrogens and intermediates used in the production thereof |
US2846453A (en) | 1957-05-28 | 1958-08-05 | Searle & Co | Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers |
US3562260A (en) | 1965-08-23 | 1971-02-09 | Ormonoterapia Richter Spa | 2-carbonyl-estratrienes and method of their preparation |
US3470218A (en) | 1966-12-27 | 1969-09-30 | Allied Chem | New 2-substituted estrogenic steroids |
US3410879A (en) | 1967-04-12 | 1968-11-12 | American Home Prod | Process for preparing gonahexaenes |
US3492321A (en) | 1968-01-22 | 1970-01-27 | Syntex Corp | Cyclopropenyl estra, -1,3,5(10)-trienes |
US3496272A (en) | 1968-01-23 | 1970-02-17 | American Home Prod | Ester of 3-(2-propynyloxy)-estradiol |
GB1502635A (en) | 1974-02-27 | 1978-03-01 | Schering Ag | Process for splitting steroid ethers |
NL7613248A (nl) | 1976-11-26 | 1978-05-30 | Akzo Nv | Werkwijze voor het bereiden van nieuwe steroid- esters. |
US4172132A (en) | 1977-07-26 | 1979-10-23 | Schering Corporation | 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor |
FR2515188A1 (fr) | 1981-10-27 | 1983-04-29 | Roussel Uclaf | Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US4552758A (en) | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
US4522758A (en) | 1983-12-22 | 1985-06-11 | Eli Lilly And Company | Method of preparing 2-fluoro-17β-estradiol |
US4634705A (en) | 1984-06-06 | 1987-01-06 | Abbott Laboratories | Adrenergic amidines |
US4743597A (en) | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
US4808402A (en) | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US6011024A (en) | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
DE4235657A1 (de) | 1992-10-22 | 1994-06-23 | Schering Ag | Verfahren zum Alkylieren von Östronderivaten |
CA2153686A1 (en) | 1993-01-11 | 1994-07-21 | Michihiko Kuwano | Angiogenesis inhibitor and novel compound |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
WO1994027635A1 (en) | 1993-05-27 | 1994-12-08 | Entremed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
US5643900A (en) | 1993-07-02 | 1997-07-01 | Fotsis; Theodore | Method for treatment of pathological conditions associated with angiogenesis and preparation therefor |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
US5504074A (en) | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US20040214807A1 (en) * | 1993-08-06 | 2004-10-28 | D'amato Robert J. | Estrogenic compounds as anti-mitotic agents |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US5885795A (en) | 1994-04-26 | 1999-03-23 | The Children's Medical Center Corporation | Methods of expressing angiostatic protein |
US5521168A (en) | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5861372A (en) | 1996-02-22 | 1999-01-19 | The Children's Medical Center Corporation | Aggregate angiostatin and method of use |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
US5854221A (en) | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
JP4228116B2 (ja) | 1996-05-09 | 2009-02-25 | ゼニス・オペレイションズ・プロプライエタリー・リミテッド | 喘息および気道の疾患の治療 |
US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
US5763432A (en) | 1997-01-29 | 1998-06-09 | Sri International | Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use |
US6136992A (en) | 1997-03-13 | 2000-10-24 | The United States Of America As Represented By The Department Of Health And Human Services | 2-alkoxy estradiols and derivatives thereof |
US6051726A (en) | 1997-03-13 | 2000-04-18 | Pharm-Eco Laboratories, Inc. | Synthesis of 2-alkoxyestradiols |
US6011023A (en) | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
US20020002294A1 (en) | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
US6046186A (en) | 1997-12-24 | 2000-04-04 | Sri International | Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use |
IL139241A0 (en) * | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
WO2000009101A2 (en) | 1998-08-11 | 2000-02-24 | Entremed, Inc. | Use of estrogenic compounds as anti-fungal agents |
US6284789B1 (en) | 1998-09-04 | 2001-09-04 | The Research Foundation Of State University Of New York | Formation and composition of new optically active compounds |
JP2002528499A (ja) | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Impdh酵素のインヒビターであるアミノ核誘導化合物 |
US20060025393A1 (en) | 1999-04-30 | 2006-02-02 | Shutsung Liao | Steroid derivatives |
US6730665B1 (en) | 1999-05-12 | 2004-05-04 | Mayo Foundation For Medical Education And Research | Treatment of bone cancer |
US7087592B1 (en) * | 1999-08-23 | 2006-08-08 | Entre Med, Inc. | Compositions comprising purified 2-methoxyestradiol and methods of producing same |
US6358940B1 (en) | 1999-09-07 | 2002-03-19 | Rutgers, The State University | Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity |
US20020068724A1 (en) | 2000-03-17 | 2002-06-06 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
US20020035098A1 (en) | 2000-03-17 | 2002-03-21 | Oncology Sciences Corporation | Agents and methods for the prevention of initial onset and recurrence of existing cancers |
US20030027803A1 (en) | 2000-03-17 | 2003-02-06 | Oncology Sciences Corporation | Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells |
US20040023863A1 (en) * | 2000-04-06 | 2004-02-05 | Franco Wayne P. | Methods of use growth factors for treating heart disease |
JPWO2001081364A1 (ja) | 2000-04-24 | 2004-01-08 | 協和醗酵工業株式会社 | エストラ−1,3,5(10)−トリエン誘導体 |
US7135581B2 (en) | 2000-08-18 | 2006-11-14 | Entremed, Inc. | Antiangiogenic agents |
US6995278B2 (en) | 2000-08-18 | 2006-02-07 | Entre Med, Inc. | Antiangiogenic agents |
AU2001279955A1 (en) * | 2000-08-18 | 2002-03-04 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
US20050192258A1 (en) | 2000-08-18 | 2005-09-01 | Agoston Gregory E. | Antiangiogenic agents |
WO2002062347A1 (en) | 2001-02-05 | 2002-08-15 | Oncology Sciences Corporation | Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis |
US20040116397A1 (en) | 2001-03-19 | 2004-06-17 | Slaga Tom J | Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers |
DK1390040T3 (da) | 2001-05-18 | 2007-04-23 | Pantarhei Bioscience Bv | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
US6593321B2 (en) | 2001-06-11 | 2003-07-15 | Southwest Foundation For Biomedical Research | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
US6448419B1 (en) | 2001-08-07 | 2002-09-10 | Tetrionics, Inc. | Synthesis of 2-hydroxyestradiol derivatives |
EP1418876A4 (en) | 2001-08-17 | 2007-07-11 | Univ Pittsburgh | OESTRADIOL METABOLITE ADMINISTRATION FOR THE TREATMENT OR PREVENTION OF OBESITY, METABOLIC SYNDROME, DIABETES AND VASCULAR AND RENAL DISORDERS |
EP1446128B1 (en) | 2001-11-15 | 2006-12-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
US20030175961A1 (en) * | 2002-02-26 | 2003-09-18 | Herron G. Scott | Immortal micorvascular endothelial cells and uses thereof |
WO2004012664A2 (en) | 2002-08-02 | 2004-02-12 | University Of Pittsburgh | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
BRPI0407667A (pt) | 2003-02-20 | 2006-03-01 | Univ Pittsburgh | metabólitos de estradiol para o tratamento de hipertensão pulmonar |
US20050148565A1 (en) | 2003-04-29 | 2005-07-07 | Cooperwood John S. | Use of aminoalkyloxy derivatives of 1,3,5(10)-Estratrien and -Estratetraene steroids in the treatment of breast cancer |
US7687486B2 (en) | 2003-04-29 | 2010-03-30 | Florida Agricultural & Mechanical University | Selective estrogen receptor modulators |
US7371741B2 (en) * | 2003-05-28 | 2008-05-13 | Entremed, Inc. | Estradiol derivatives and pharmaceutical compositions using same |
AU2005222934B2 (en) | 2004-03-12 | 2010-06-17 | Entremed, Inc. | Antiangiogenic agents |
WO2006058298A2 (en) | 2004-11-29 | 2006-06-01 | Entremed, Inc. | A method of administering anti-angiogenic agents and a method of treating disease using same |
-
2004
- 2004-05-28 US US10/856,340 patent/US7371741B2/en not_active Expired - Fee Related
- 2004-05-28 EP EP04809420A patent/EP1633367A2/en not_active Withdrawn
- 2004-05-28 CA CA002527074A patent/CA2527074A1/en not_active Abandoned
- 2004-05-28 AU AU2004275693A patent/AU2004275693A1/en not_active Abandoned
- 2004-05-28 JP JP2006514998A patent/JP2006526025A/ja not_active Withdrawn
- 2004-05-28 WO PCT/US2004/016831 patent/WO2005030120A2/en active Application Filing
-
2006
- 2006-09-12 US US11/519,570 patent/US20070010505A1/en not_active Abandoned
-
2007
- 2007-02-02 US US11/701,809 patent/US20070135400A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006526025A5 (ja) | ||
JP2007529426A5 (ja) | ||
DE60118547T2 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
JP2020037585A5 (ja) | ||
US20160287569A1 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
DE602004004520T2 (de) | Antineoplastische zusammensetzungen | |
WO2021055728A8 (en) | Small molecule inhibitors of kras g12c mutant | |
CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
JP2018521092A5 (ja) | ||
JP2008521928A5 (ja) | ||
JP2006506466A5 (ja) | ||
JP2020512337A5 (ja) | ||
JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
AU764445B2 (en) | Use of pyridazino(4,5-(b))indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors | |
JP2020500866A5 (ja) | ||
EP2089021B1 (en) | Use of carboxyamidotriazole (cai) orotate in macular degeneration | |
NZ579689A (en) | Solid forms of (e) -1- (4- ( (ir, 2s, 3r) -1, 2, 3, 4-tetrahydroxybutyl) -1h-imidazol-2-yl) ethanone oxime | |
RU2326867C2 (ru) | Цианогуанидиновые производные, способ лечения и фармацевтическая композиция на их основе | |
EP4157290A1 (en) | Compositions, their uses in therapy and methods thereof | |
JP2002514578A5 (ja) | ||
WO2004053067A2 (en) | Methods for inhibiting cancer and scar formation | |
WO2013155218A1 (en) | Chirally pure isomers of itraconazole for use as angiogenesis inhibitors | |
Moertel et al. | Brief Communication: Therapy of Advanced Colorectal Cancer With a Combination of 5-Flourouracil, Methyl-l, 3-cis (2-chlorethyl)-1-nitrosourea, and Vincristine | |
US20230090414A1 (en) | Physics-driven discovery of novel small therapeutic compounds for use as a bcl-2 inhibitor |